Last year, Oncode Institute completed its first five-year operational phase, paving the way for the launch of Phase 2. This transition period was a challenging one, requiring maximum efforts from the Managing Board and the Oncode Institute team, who kept the operational engine running and continued to support the researchers with their work. We consider it a great achievement that by the end of 2022, the conditions required for continuation of Oncode Institute for another five-year period have been met. Securing a commitment of €92M from our funders means we can continue our mission to outsmart cancer and impact patients’ lives.

Oncode Institute’s success isn't just about funding, though. It's about creating a fertile environment for the best minds in cancer research to think big, take risks, and make the kind of discoveries that redefine our understanding of the disease. And let's just say, 2022 was a very fruitful year. Our research community  authored an astonishing 404 peer-reviewed publications, and earned prestigious grants and awards. 

Recognizing that collaboration breeds innovation, Oncode Institute nurtures a unique environment where researchers from different fields come together to tackle cancer's most stubborn mysteries. The results of this strategy have been impressive, leading to over 50 active public-private research collaborations and the initiation of 4.UNCAN.eu – an EU-funded project involving institutes across 20 member states.

Our proactive Valorization Team takes promising research findings and transforms them into practical applications, leading to breakthroughs in cancer diagnosis and therapy. Their work resulted in 183 research-related agreements in 2022, multiple patent applications and the launch of two spin-off companies.

Finally, let’s not forget Oncode Institute’s goal to impact patients’ lives. Cancer patients and oncology researchers are inherently linked, but rarely meet. Bringing researchers and patients together provides opportunities for researchers to access first-hand knowledge and improve their research through novel ideas, perspectives, and discussions; while patients gain insight into the science underlying their disease, can have their questions answered, and provide valuable input to advance oncology research.

Our dedicated Patient Engagement Program enables researchers and (ex-)patients to connect and interact and has made great progress in 2022.

Overall, the Oncode Institute annual report offers a comprehensive overview of the institute's significant progress and successes in 2022. It showcases the strategic planning, rigorous research, and successful collaborations that have enabled Oncode Institute to make strides in the battle against cancer. It's a testament to the power of dedicated research and a unified scientific community. Whether you're an industry professional, a science enthusiast, an (ex-)patient or simply someone interested in the fight against cancer, Oncode Institute’s annual report is a worthy read.

Oncode Managing Board